Treatment toxicity and efficacy in 218 patients with lymphoma who had an HIV score of 0, according to HAART era
. | Before HAART . | . | After HAART . | . | ||
|---|---|---|---|---|---|---|
| Patients with HIV score of 0 . | ACVBP . | CHOP . | ACVBP . | CHOP . | ||
| Toxicity grade 3-4, no. (%) | ||||||
| Platelets | 25 (37)* | 8 (12)* | 25 (59)* | 5 (11)* | ||
| Leukocytes | 47 (70)* | 20 (31)* | 35 (83)* | 19 (43)* | ||
| Infection | 17 (25)* | 4 (6)* | 11 (26)* | 2 (5)* | ||
| Response to chemotherapy | ||||||
| CR/Cru, no. (%) | 44 (66) | 35 (54) | 22 (52) | 21 (48) | ||
| 3-y OS, % (95% CI) | 46 (34, 59) | 40 (28, 52) | 60 (45, 75) | 57 (43, 72) | ||
| 3-y EFS, % (95% CI) | 40 (28, 52) | 32 (20, 44) | 53 (37, 68) | 48 (33, 63) | ||
| 3-y DFS, % (95% CI) | 50 (35, 65) | 45 (28, 63) | 71 (51, 90) | 55 (32, 78) | ||
. | Before HAART . | . | After HAART . | . | ||
|---|---|---|---|---|---|---|
| Patients with HIV score of 0 . | ACVBP . | CHOP . | ACVBP . | CHOP . | ||
| Toxicity grade 3-4, no. (%) | ||||||
| Platelets | 25 (37)* | 8 (12)* | 25 (59)* | 5 (11)* | ||
| Leukocytes | 47 (70)* | 20 (31)* | 35 (83)* | 19 (43)* | ||
| Infection | 17 (25)* | 4 (6)* | 11 (26)* | 2 (5)* | ||
| Response to chemotherapy | ||||||
| CR/Cru, no. (%) | 44 (66) | 35 (54) | 22 (52) | 21 (48) | ||
| 3-y OS, % (95% CI) | 46 (34, 59) | 40 (28, 52) | 60 (45, 75) | 57 (43, 72) | ||
| 3-y EFS, % (95% CI) | 40 (28, 52) | 32 (20, 44) | 53 (37, 68) | 48 (33, 63) | ||
| 3-y DFS, % (95% CI) | 50 (35, 65) | 45 (28, 63) | 71 (51, 90) | 55 (32, 78) | ||
For pre-HAART patients on ACVBP, n = 67; on CHOP, n = 65. For post-HAART patients on ACVBP, n = 42; on CHOP, n = 44.
Comparison between treatment arms within the HAART era: P ≤ .01.